IHC PD-L1/CD274 on a Small Lymphotic Lymphoma Tissue

Specification Sheets
Safety Data Sheet


Intended Use For In Vitro Diagnostic Use
Summary and Explanation

Programmed death-ligand 1 (PD-L1) also known as CD274 or B7 homolog 1 (B7-H1) is a protein that in humans is encoded by the CD274 gene. Programmed death-ligand 1 (PD-L1) is a 40 kDa type 1 transmembrane protein that has been speculated to play a major role in suppressing the immune system during events such as pregnancy, tissue allografts, autoimmune disease and other diseases.

The upregulation of PD-L1 may allow cancers to evade the host immune system. An analysis of tumor specimens from patients with renal cell carcinoma found that high tumor expression of PD-L1 was associated with increased tumor aggressiveness and a 4.5-fold increased risk of death. Ovarian cancer patients with higher expression of PDL1 had a significantly poorer prognosis than those with lower expression. PD-L1 expression correlated inversely with intraepithelial CD8+ T-lymphocyte count, suggesting that PD-L1 on tumor cells may suppress antitumor CD8+ T cells. The PD1/PD-L1 interaction is implicated in autoimmunity from several lines of evidence. In humans, PD-L1 was found to have altered expression in pediatric patients with Systemic lupus erythematosus. Studying isolated PBMC from healthy children, immature myeloid dendritic cells and monocytes expressed little PD-L1 at initial isolation, but spontaneously up-regulated PD-L1 by 24 hours. In contrast, both mDC and monocytes from patients with active SLE failed to upregulate PD-L1 over a 5-day time course, expressing this protein only during disease remissions

Antibody Type Rabbit  Monoclonal Clone 28-8
Isotype IgG Reactivity Paraffin, Frozen
Localization Membranous Control Tonsil, Placenta, Lymphoblastic Lymphoma
Presentation Anti-PD-L1/CD274 is a rabbit monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.
Catalog No. Antibody Type Dilution Volume/QTY
BSB-2371-3 TintoPredilute Ready-To-Use 3.0 ml
BSB-2371-7 TintoPredilute Ready-To-Use 7.0 ml
BSB-2371-15 TintoPredilute Ready-To-Use 15.0 ml
BSB-2371-01 Concentrate 1:25-1:100 0.1 ml
BSB-2371-05 Concentrate 1:25-1:100 0.5 ml
BSB-2371-1 Concentrate 1:25-1:100 1.0 ml
BSB-2371-CS Control Slides 5
Note: For concentrated antibodies, please centrifuge prior to use to ensure recovery of all product.
Related Products